New asthma guidelines emphasize control, regular monitoring

Cleveland Clinic Journal of Medicine

Volumn 75, Issue 9, 2008, Pages 641-653

  Lang, David M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT;

ASTHMA; HUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REVIEW;

ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC;

EID: 52949120963     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.75.9.641     Document Type: Review

References (70)

1. National Heart, Lung, and Blood institute, National Asthma education and Prevention Program. Expert Panel Report 3: guidelines for the diagnosis and management of asthma. www.nhlbi.nih.gov/guidelines/asthma/. Accessed 8/7/08.
2. Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. U.S. Department of Health and Human Services. Publication No. 97-4051; 1997.
3. Expert Panel Report: Guidelines for the diagnosis and management of asthma. Update on Selected Topics - 2002. J Allergy Clin Immunol 2002; 110:S141-S207.
4. FitzGerald JM, Boulet LP, Mdvor RA, Zimmerman S, Chapman KR. Asthma control in Canada remains suboptimal: the Reality of Asthma Control (TRAC) study. Can Respir J 2006; 13:253-259.
5. Braganza S, Sharif I, Ozuah P. Documenting asthma severity: do we get it right? J Asthma 2003; 40:661-665.
6. Cockcroft DW, Swystun VA. Asthma control versus asthma severity. J Allergy Clin Immunol 1996; 98:1016-1018.
7. Peters SP, Jones CA, Haselkom T, Mink DR, Valacer DJ, Weiss ST. Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey. J Allergy Clin Immunol. 2007;119:1454-1461.
8. Osborne ML, Vollmer WM, Pedula KL, Wilkins J, Buist AS, O'Hollaren M. Lack of correlation of symptoms with specialist-assessed long-term asthma severity. Chest 1999; 115:85-91.
9. Li JT, Oppenheimer J, Bernstein IL, et al. Attaining optimal asthma control: a practice parameter. J Allergy Clin Immunol 2005; 116:S3-S11.
10. Nathan RA, Sorkness C, Kosinski M, et al. Development of the Asthma Control Test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59-65.
11. Schatz M, Zeiger RS, Drane A, et al. Reliability and predictive validity of the Asthma Control Test administered by telephone calls using speech recognition technology. J Allergy Clin Immunol 2007; 119:336-343.
12. Peters D, Chen C, Markson LE, Allen-Ramey FC, Vollmer WM. Using an asthma control questionnaire and administrative data to predict healthcare utilization. Chest 2006; 129:918-924.
13. Schatz M, Sorkness C, Li JT, et al. Asthma Control Test: reliability validity and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006; 117:549-556.
14. Bateman E, Boushey H, Bousquet J, et al. Can guideline-defined asthma control be achieved? Am J Respir Crit Care Med 2004; 170:836-844.
15. Davies TJ, Bunn WB, Fromer L, Gelfand EW, Colice GL. A focus on the asthma HEDIS measure and its implications for clinical practice. Manag Care Interface 2006; 19:29-36.
16. Rubinfeld AR, Pain MC. Perception of asthma. Lancet 1976; 1:882-884.
17. Teeter J, Bleecker E. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest 1998; 113:272-277.
18. Shingo S, Zhang J, Reiss T. Correlation of airway obstruction and patient reported endpoints in clinical studies. Eur Rasp J 2001; 17:220-224.
19. Juniper EF, Bousquet J, Abetz L, Bateman ED; GOAL Committee. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 2006; 100:616-621.
20. Nelson H, Weiss S, Bleecker E, Yancey S, Dorinsky P. The Salmeterol Multicenter Asthma Research Trial. Chest 2006; 129:15-26.
21. Wechsler M, Lehman E, Lazarus S, et al. β-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173:519-526.
22. Palmer CNA, Lipworth BJ, Lee S, Ismail T, MacGregor DF, Mukhopadhyay S. Arginine-16 beta-2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 2006; 61:940-944.
23. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta 2 adrenoceptor polymorphism. Thorax 2000;55:762-727.
24. Bleecker E, Postma D, Lawrance R, Meyers D, Ambrose H, Goldman M. Effect of ADRB2 polymorphisms on response to long-acting beta2-agonist therapy: a pharmacogenetic analysis of two randomized studies. Lancet 2007; 370:2118-2125.
25. Bleecker E, Yancey S, Baitinger L, et al. Salmeterol response is not affected by beta-2 adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006; 118:809-816.
26. Nelson H, Bleecker E, Corren J, et al. Characterization of asthma exacerbations by Arg16Gly genotype in subjects with asthma receiving salmeterol alone or with fluticasone propionate. J Allergy Clin Immunol 2008; 121:S131.
27. O'Byrne P, Barnes P, Rodriguez-Roisin R, et al. Low dose Inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA Randomized Trial. Am J Respir Crit Care Med 2001; 164:1392-1397.
28. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344:219-224.
29. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481-1488.
30. Walters EH, Walters JAE, Gibson MDP. Long-acting beta2-agonists for stable chronic asthma. Cochrane Database Syst Rev 2003; (3): CD001385. DOI: 10.1002/14651858.CD001385.
31. Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroid in symptomatic asthma. Thorax 2005; 60:730-734.
32. Sin DD, Man J, Sharpe H, Gan WQ, Man SFP. Pharmacological management to reduce exacerbations in adults with asthma. A systematic review and meta-analysis. JAMA 2004; 292:367-376.
33. Mann RD, Kubota K, Pearce G, Wilton L. Salmeterol: a study by prescription event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol 1996; 49:247-250.
34. Lanes S, Lanza L, Wentworth C. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. Am J Respir Crit Care Med 1998; 158:857-861.
35. Meier CR, Jick H. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Thorax 1997; 52:612-617.
36. Williams C, Crossland L, Finnerty J, et al. A case control study of salmeterol and near-fatal attacks of asthma. Thorax 1998; 53:7-13.
37. Lanes S, Garcia Rodriguez LA, Herta C. Respiratory medications and risk of asthma death. Thorax 2002; 57:683-686.
38. Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths from asthma: case control study. Br Med J 2005; 330:117-124.
39. Martinez FD. Safety of long-acting beta agonists - an urgent need to clear the air. N Engl J Med 2005; 353:2637-2639.
40. Nelson HS. Long-acting beta-agonists in adult asthma: evidence that these drugs are safe. Prim Care Respir J 2006; 15:271-277.
41. Lang DM. The long-acting beta agonist controversy: a critical examination of the evidence. Cleve Clin J Med 2006; 73:973-992.
42. Rambasek T, Lang DM, Kavuru M. Omalizumab: where does it fit in current asthma management? Cleve Clin J Med 2004; 71:251-261.
43. McGlashan D, Bochner B, Adelman D, et al. Down regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158:1438-1445.
44. Busse W, Corren J, Lanier B, et al. Omalizumab anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190.
45. Soler M, Matz J, Townley R et al. The anti-IgE antibody omalizu-mab reduces asthma exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-261.
46. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309-316.
47. Van Ganse E, Antonicelli L, Zhang Q, et al. Asthma-related resource use and cost by GINA classification of severity in three European countries. Respir Med 2006; 100:140-147.
48. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19:61-67.
49. Cisternas MG, Blanc PH, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003; 111:1212-1218.
50. Sullivan S, Turk F. An evaluation of the cost effectiveness of omalizumab for the treatment of severe persistent asthma. Allergy 2008; 63:670-684.
51. US Food and Drug Administration. Omalizumab (marketed as Xolair) information. www.fda.gov/cder/drug/infopage/omalizumab/default.htm. Accessed August 31, 2007.
52. Williams SG, Schmidt DK, Redd SC, Storms W. Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program. MMWR Recomm Rep 2003; 52(RR-6):1-8.
53. Cox L, Li J, Nelson H, Lockey R, et al. Allergy Immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007; 120:S25-S85.
54. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007; 119:780-789.
55. Murray AB, Milner RA. The accuracy of features in the clinical history for predicting atopic sensitization to airborne allergens in children. J Allergy Clin Immunol 1995; 96:588-596.
56. Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol 2008; 100(suppl 3):1S-148S.
57. Walker S, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized controlled trial. J Allergy Clin Immunol 2001; 107:87-93.
58. Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997; 27:860-867.
59. Cantani A, Arcese G, Lucenti P, Gagliesi D, Bartolucci M. A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma. J Investig Allergol Clin Immunol 1997; 7:90-97.
60. Hedlin G, Wille S, Browaldh L, et al. Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. J Allergy Clin Immunol 1999; 103:609-614.
61. Arvidsson MB, Löwhagen O, Rak S. Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study. Allergy 2004; 59:74-80.
62. Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 2001; 56:301-306.
63. Mirone C, Albert F, Tosi A, et al. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind placebo-controlled study. Clin Exp Allergy 2004; 34:1408-1414.
64. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003; (4):CD001186.
65. Jacobsen L. Preventive aspects of immunotherapy: prevention for children at risk of developing asthma. Ann Allergy Asthma Immunol 2001; 87:43-46.
66. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT study). J Allergy Clin Immunol 2002; 109:251-256.
67. Niggemann B, Jacobsen L, Dreborg S, et al; PAT Investigator Group. Five year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006: 61:855-859.
68. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract VI: specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99:450-453.
69. Pajno GB, Barberio G, DeLuca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to the house dust mite by specific immunotherapy: a six year follow up study. Clin Exp Allergy 2001; 31:1392-1397.
70. Lang DM. Do beta blockers really enhance the risk of anaphylaxis during immunotherapy? Curr Allergy Asthma Rep 2008; 8:37-44.